Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial

Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patient...

Full description

Saved in:
Bibliographic Details
Published inJournal of psychopharmacology (Oxford) Vol. 33; no. 8; p. 1030
Main Authors Lin, C-H, Chen, P-K, Wang, S-H, Lane, H-Y
Format Journal Article
LanguageEnglish
Published United States 01.08.2019
Subjects
sodium benzoate
D-amino acid oxidase (DAAO) inhibitor
methyl-D-aspartate
Behavioral and psychological symptoms of dementia (BPSD)
Online AccessGet more information

Cover

More Information
Summary:Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Two treatments showed similar safety and primary and secondary outcomes. Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.
ISSN:1461-7285
DOI:10.1177/0269881119849815